CA2762095A1 - Compositions comprising cationic amphiphiles and colipids for delivering therapeutic molecules - Google Patents

Compositions comprising cationic amphiphiles and colipids for delivering therapeutic molecules Download PDF

Info

Publication number
CA2762095A1
CA2762095A1 CA2762095A CA2762095A CA2762095A1 CA 2762095 A1 CA2762095 A1 CA 2762095A1 CA 2762095 A CA2762095 A CA 2762095A CA 2762095 A CA2762095 A CA 2762095A CA 2762095 A1 CA2762095 A1 CA 2762095A1
Authority
CA
Canada
Prior art keywords
solution
cholesterol
peg
nucleic acid
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2762095A
Other languages
English (en)
French (fr)
Inventor
Kunyuan Cui
Dong Liang
David Sweedler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2762095A1 publication Critical patent/CA2762095A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2762095A 2009-05-16 2010-05-16 Compositions comprising cationic amphiphiles and colipids for delivering therapeutic molecules Abandoned CA2762095A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17896209P 2009-05-16 2009-05-16
US61/178,962 2009-05-16
PCT/US2010/035049 WO2010135207A1 (en) 2009-05-16 2010-05-16 Compositions comprising cationic amphiphiles and colipids for delivering therapeutics molecules

Publications (1)

Publication Number Publication Date
CA2762095A1 true CA2762095A1 (en) 2010-11-25

Family

ID=43126456

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2762095A Abandoned CA2762095A1 (en) 2009-05-16 2010-05-16 Compositions comprising cationic amphiphiles and colipids for delivering therapeutic molecules

Country Status (7)

Country Link
US (1) US9080186B2 (enExample)
EP (1) EP2430168B1 (enExample)
JP (1) JP5675784B2 (enExample)
CN (1) CN102985548B (enExample)
AU (1) AU2010249881B2 (enExample)
CA (1) CA2762095A1 (enExample)
WO (1) WO2010135207A1 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010008582A2 (en) 2008-07-18 2010-01-21 Rxi Pharmaceuticals Corporation Phagocytic cell drug delivery system
CN108165548B (zh) 2008-09-22 2022-10-14 菲奥医药公司 减小大小的自递送RNAi化合物
WO2010078536A1 (en) 2009-01-05 2010-07-08 Rxi Pharmaceuticals Corporation Inhibition of pcsk9 through rnai
IN2012DN00570A (enExample) 2009-07-14 2015-06-12 Polypid Ltd
AU2011208374B2 (en) 2010-01-19 2016-09-08 Polypid Ltd. Sustained-release nucleic acid matrix compositions
FR2998899B1 (fr) * 2012-11-30 2015-07-17 Commissariat Energie Atomique Methode de criblage a haut-debit pour l'identification de biomarqueurs, cibles therapeutiques ou d'agents therapeutiques
US10253315B2 (en) 2012-08-30 2019-04-09 Commissariat A L'energie Atomique Et Aux Energies Alternatives Method for transfection of nucleic acids into eukaryotic cells in 3D scaffold
FR2994849B1 (fr) * 2012-08-30 2015-01-02 Commissariat Energie Atomique Formulation pour la delivrance de sequences nucleotidiques susceptibles de moduler des mecanismes endogenes d'arn interferents
EP2719765A1 (de) * 2012-10-11 2014-04-16 Secutech International Pte. Ltd. Ex vivo-Verfahren zur Einbringung von Nukleinsäuren in Zellen
JP6400479B2 (ja) * 2012-10-29 2018-10-03 株式会社カルディオ 肺疾患特異的治療剤
EP3027222A1 (en) * 2013-07-31 2016-06-08 QBI Enterprises Ltd. Sphingolipid-polyalkylamine-oligonucleotide compounds
WO2015184326A1 (en) * 2014-05-30 2015-12-03 Cerulean Pharma Inc. Conjugates, particles, compositions, and related methods
US20150368648A1 (en) 2014-06-20 2015-12-24 Yale University Compositions and methods of inhibiting gene expression in a lung
KR101671864B1 (ko) * 2014-08-29 2016-11-04 세종대학교 산학협력단 요오드화 오일을 함유하는 양이온성 에멀젼 및 바이러스 벡터의 유전자 전달 증진을 위한 이의 용도
CN104922141B (zh) * 2015-05-28 2016-05-25 厦门成坤生物技术有限公司 一种用于治疗乙型病毒性肝炎的siRNA组合物
CN105079021A (zh) * 2015-08-03 2015-11-25 厦门成坤生物技术有限公司 包含m10c1化合物与活性成分的组合物及其制备方法
DK3350157T3 (da) 2015-09-17 2022-02-14 Modernatx Inc Forbindelser og sammensætninger til intracellulær afgivelse af terapeutiske midler
AU2016377681B2 (en) 2015-12-22 2021-05-13 Modernatx, Inc. Compounds and compositions for intracellular delivery of agents
WO2017151733A1 (en) * 2016-03-01 2017-09-08 Molecular Transfer, Inc. Plant virus movement proteins and methods of using the same
US11583504B2 (en) 2016-11-08 2023-02-21 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
AU2018234692B2 (en) 2017-03-15 2022-06-02 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
CA3055653A1 (en) * 2017-03-15 2018-09-20 Modernatx, Inc. Lipid nanoparticle formulation
WO2018232120A1 (en) 2017-06-14 2018-12-20 Modernatx, Inc. Compounds and compositions for intracellular delivery of agents
CN107802508A (zh) * 2017-11-01 2018-03-16 武汉百思凯瑞纳米科技有限公司 一种阳离子脂质体纳米组合物及其制备方法和应用
KR102056144B1 (ko) 2018-03-08 2019-12-16 주식회사 파마리서치프로덕트 Dna 단편 혼합물이 고농도로 함유된 유동성을 갖는 액제 조성물 및 이의 제조방법
US12263248B2 (en) 2018-09-19 2025-04-01 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
WO2020061317A1 (en) * 2018-09-19 2020-03-26 Modernatx, Inc. Sterol purification
WO2020061332A1 (en) * 2018-09-19 2020-03-26 Modernatx, Inc. Sterol analogs and uses thereof
CA3154618A1 (en) 2019-09-19 2021-03-25 Modernatx, Inc. Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
CN111904934B (zh) * 2020-09-21 2022-02-25 中国医学科学院医药生物技术研究所 miRNA185抑制剂的脂质体及其制法
CN120775847A (zh) 2021-10-20 2025-10-14 厦门甘宝利生物医药有限公司 Agt抑制剂及其用途
EP4495130A4 (en) * 2022-03-15 2025-12-17 Fujifilm Corp CONNECTION AND LIPIDE COMPOSITION
WO2023229023A1 (ja) * 2022-05-25 2023-11-30 学校法人 名城大学 粉末剤及びその製造方法
CN116814621B (zh) 2022-08-05 2025-09-09 厦门甘宝利生物医药有限公司 一种抑制apoc3基因表达的rna抑制剂及其应用
CN115197431B (zh) * 2022-09-15 2022-11-29 清华大学 脂质偶联完全可降解水溶性聚合物的合成及应用
CN115851723B (zh) 2022-10-24 2023-10-03 厦门甘宝利生物医药有限公司 一种抑制lpa基因表达的rna抑制剂及其应用
WO2025021083A1 (en) * 2023-07-24 2025-01-30 National Institute Of Biological Sciences, Beijing Lipid nanoparticle compositions for localized treatment of skin diseases

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3272873D1 (en) 1981-06-04 1986-10-02 Pharmasol Corp Pressurized container with dispensing pump
US5208036A (en) 1985-01-07 1993-05-04 Syntex (U.S.A.) Inc. N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4778810A (en) 1987-01-08 1988-10-18 Nastech Pharmaceutical Co., Inc. Nasal delivery of caffeine
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
DE69123979T2 (de) 1990-10-12 1997-04-30 Max Planck Gesellschaft Abgeänderte ribozyme
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US5652094A (en) 1992-01-31 1997-07-29 University Of Montreal Nucleozymes
DE69527206T2 (de) 1994-09-30 2003-02-27 Inex Pharmaceuticals Corp., Vancouver Mittel zum einbringen polyanionischer materialien in zellen
US5753613A (en) 1994-09-30 1998-05-19 Inex Pharmaceuticals Corporation Compositions for the introduction of polyanionic materials into cells
US5767099A (en) 1994-12-09 1998-06-16 Genzyme Corporation Cationic amphiphiles containing amino acid or dervatized amino acid groups for intracellular delivery of therapeutic molecules
US5948767A (en) 1994-12-09 1999-09-07 Genzyme Corporation Cationic amphiphile/DNA complexes
US6331524B1 (en) * 1994-12-09 2001-12-18 Genzyme Corporation Organ-specific targeting of cationic amphiphile / DNA complexes for gene therapy
US20020022264A1 (en) * 1995-05-26 2002-02-21 Sullivan Sean M. Delivery vehicles comprising stable lipid/nucleic acid complexes
US7422902B1 (en) * 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5849902A (en) 1996-09-26 1998-12-15 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
US6358523B1 (en) 1996-12-06 2002-03-19 The Regents Of The University Of California Macromolecule-lipid complexes and methods for making and regulating
JP2002524473A (ja) 1998-09-09 2002-08-06 ジエンザイム コーポレイション プラスミドベクターのメチル化
WO2002087541A1 (en) * 2001-04-30 2002-11-07 Protiva Biotherapeutics Inc. Lipid-based formulations for gene transfer
SG190613A1 (en) * 2003-07-16 2013-06-28 Protiva Biotherapeutics Inc Lipid encapsulated interfering rna
EP1664316B1 (en) * 2003-09-15 2012-08-29 Protiva Biotherapeutics Inc. Polyethyleneglycol-modified lipid compounds and uses thereof
JP4764426B2 (ja) 2004-06-07 2011-09-07 プロチバ バイオセラピューティクス インコーポレイティッド カチオン性脂質および使用方法
US8598333B2 (en) * 2006-05-26 2013-12-03 Alnylam Pharmaceuticals, Inc. SiRNA silencing of genes expressed in cancer
US20080299177A1 (en) * 2007-06-06 2008-12-04 Biovaluation & Analysis, Inc. Supramolecular Complexes for Use in Acoustically Mediated Intracellular Drug Delivery in vivo
WO2011084721A2 (en) 2009-12-21 2011-07-14 Agave Pharma Inc Cationic molecule and method of use

Also Published As

Publication number Publication date
WO2010135207A1 (en) 2010-11-25
CN102985548A (zh) 2013-03-20
EP2430168B1 (en) 2016-12-21
CN102985548B (zh) 2016-10-26
JP5675784B2 (ja) 2015-02-25
AU2010249881B2 (en) 2015-01-22
US20120289584A1 (en) 2012-11-15
EP2430168A1 (en) 2012-03-21
JP2012526858A (ja) 2012-11-01
AU2010249881A1 (en) 2012-01-19
US9080186B2 (en) 2015-07-14
EP2430168A4 (en) 2013-11-27

Similar Documents

Publication Publication Date Title
AU2010249881B2 (en) Compositions comprising cationic amphiphiles and colipids for delivering therapeutics molecules
US9670152B2 (en) Ionizable cationic lipid for RNA delivery
KR101762466B1 (ko) 지질, 지질 조성물 및 이의 사용 방법
DK2494993T3 (en) Amino acid lipids and uses thereof
CN103189057B (zh) 大环脂类化合物及其应用
CN112533909A (zh) 维生素阳离子脂质
JP2021525744A (ja) ステロイド性部分を含むカチオン性脂質
AU2018204605A1 (en) Processes and compositions for liposomal and efficient delivery of gene silencing therapeutics
CA3219192A1 (en) Ionizable cationic lipids for rna delivery
JP2022512945A (ja) 層間エステル、チオエステル、ジスルフィドおよび無水部分を含む２，５－ジオキソピペラジン脂質
CN114716355A (zh) 一种脂质化合物、包含其的组合物及应用
JP2025518221A (ja) 核酸の送達のための複合体
CN101475503A (zh) 一种新型阳离子类脂及其制备方法和应用
WO2025011532A1 (en) Lipid compounds for delivery of therapeutic agents and preparation method and its use thereof
CN116199666B (zh) 两亲性化合物及其药物组合物
JP6774965B2 (ja) カチオン性脂質としての化合物
JP4629333B2 (ja) アミノグリコシドの脂質誘導体
WO2025043730A1 (en) Lipid compounds for delivery of therapeutic agents and preparation method and use thereof
JP4276439B2 (ja) ポリチオ尿素の脂質誘導体
EP4491615A1 (en) Lipids for active agent delivery
HK1158059A (en) Processes and compositions for liposomal and efficient delivery of gene silencing therapeutics

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150430

FZDE Discontinued

Effective date: 20170818